Combining stereotactic body radiation therapy with immunotherapy: Current data and future directions

Alexander J. Lin, Michael Roach, Jeffrey Bradley, Clifford Robinson

Research output: Contribution to journalReview article

6 Scopus citations

Abstract

Stereotactic body radiation therapy (SBRT) offers excellent local control of early-stage non-small cell lung cancer (NSCLC), but there currently is a need for tolerable systemic therapy to address regional and distant disease progression. One potential option is immunotherapy, which in metastatic NSCLC has shown promise for sustained disease control in a subset of patients. There is also growing evidence for a clinical synergy between radiation and immunotherapy, with several ongoing trials studying the abscopal effect. This review summarizes the current data in the fast-changing field of immuno-radiation therapy, highlighting updates from recent clinical trials.

Original languageEnglish
Pages (from-to)107-115
Number of pages9
JournalTranslational Lung Cancer Research
Volume8
Issue number1
DOIs
StatePublished - Feb 1 2018

Keywords

  • Checkpoint inhibitor
  • Immunotherapy
  • Lung cancer
  • Stereotactic ablative radiotherapy
  • Stereotactic body radiation therapy (SBRT)

Fingerprint Dive into the research topics of 'Combining stereotactic body radiation therapy with immunotherapy: Current data and future directions'. Together they form a unique fingerprint.

  • Cite this